Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702094 | 1.00 | CNR1 (0.68) | CNR1CNR2 | |
| SCHEMBL702213 | 0.85 | CNR1 (0.68) | CNR1CNR2 | |
| SCHEMBL707898 | 0.85 | CNR1 (0.68) | CNR1CNR2 | |
| SCHEMBL27782682 | 0.85 | CNR1 (0.72) | CNR1CNR2 | |
| SCHEMBL701613 | 0.85 | CNR1 (0.72) | CNR1CNR2 | |
| SCHEMBL702982 | 0.82 | CNR1 (0.73) | CNR1 | |
| SCHEMBL10087191 | 0.81 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL700577 | 0.78 | CNR1 (0.76) | CNR1CNR2 | |
| SCHEMBL709250 | 0.78 | CNR1 (0.76) | CNR1CNR2 | |
| SCHEMBL703804 | 0.78 | CNR1 (0.76) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121617-B1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA AS (DK) | 2014-01-22 | — | — | EP | disclosed |
| US-8124598-B2 | Administering 3-acetyl-7-oxo-dehydroepiandrosterone (7-keto DHEA) together with a carrier to treat to improve symptoms of depression, anxiety, bipolar, trauma; antiglucocorticoid; neuroprotective | SAGEMAN SHARON (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124634-B2 | CB1 receptor modulators | 7TM PHARMA A/S (DK) | 2012-02-28 | — | — | US | disclosed |
| EP-2382983-A1 | Improved ApoE analogs and methods for their use | Cosnosci, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| US-7947645-B2 | APO E analogs and methods for their use | COGNOSCI, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA A/S (DK) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | CNR1, CNR2, GPR6 | CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.